Is Beta Bionics, Inc. Common Stock (BBNX) overvalued? · rev $100.3M
Beta Bionics, Inc. Common Stock (BBNX) is a medical devices company listed on NASDAQ.
This page asks whether Beta Bionics, Inc. Common Stock (BBNX) looks expensive on cached numbers — not a short thesis.
Latest reported BBNX revenue for 2025-12-31 was $100.3M. Net income was -$73.2M. Revenue was up 53.9% from 2024-12-31 to 2025-12-31. BBNX currently screens at market cap $640.8M.
BBNX currently screens at market cap $640.8M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BBNX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BBNX stock page for the full model, not this heading.
Not investment advice.